Skip to content

Decreasing Nightmares in Adults With Narcolepsy

Imagery Rehearsal Therapy for the Treatment of Nightmares in Narcolepsy: A Pilot Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06383806
Acronym
DAWN
Enrollment
80
Registered
2024-04-25
Start date
2026-07-01
Completion date
2027-09-01
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Nightmare, Nightmare Disorder With Associated Other Sleep Disorder

Keywords

Imagery Rehearsal Therapy, Cognitive Behavioral Therapy for Nightmares

Brief summary

The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. Romantic partners of participants with narcolepsy will also be eligible to enroll in the study. Partners will complete three assessments but will not participate in the treatment.

Interventions

The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Waitlist control

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

PARTICIPANTS WITH NARCOLEPSY/NIGHTMARES Inclusion Criteria: * Diagnosis of narcolepsy type 1 or narcolepsy type 2 * Nightmare frequency of ≥1 times per week * Age 18 or older * Able to speak, read, and write in English * Live in the United States * Sleep and psychiatric medications stable for ≥ 1 month and willing to keep medications stable for the duration of the study

Exclusion criteria

* Currently engaged in trauma- or sleep-related psychotherapy * Previous behavioral treatment for nightmares * Medical, psychiatric, or cognitive condition which would interfere with ability to engage in the treatment * Untreated moderate-severe sleep apnea PARTICIPANTS WHO ARE PARTNERS OF SOMEONE WITH NARCOLEPSY Inclusion Criteria: * Live with a romantic partner who meets the above criteria and has agreed to participate in the study * Age 18 or older * Able to speak, read, and write in English * Live in the United States

Design outcomes

Primary

MeasureTime frameDescription
Disturbing Dream and Nightmare Severity Index (DDNSI)Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)The DDNSI is a questionnaire which measures the severity of nightmares.
Nightmare frequency (sleep diary)Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)The number of nightmares experienced each day will be collected on daily sleep diaries completed during each assessment period.

Secondary

MeasureTime frameDescription
PROMIS AnxietyCompleted at each of the three assessments (baseline, 10 weeks, 19 weeks)Questionnaire which measures the severity of anxiety symptoms.
PROMIS DepressionCompleted at each of the three assessments (baseline, 10 weeks, 19 weeks)Questionnaire which measures the severity of depressive symptoms.

Countries

United States

Contacts

CONTACTJennifer Mundt, PhD
DAWNstudy@utah.edu801-646-8287

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026